PMID- 30396967
OWN - NLM
STAT- MEDLINE
DCOM- 20181113
LR  - 20181113
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 11
DP  - 2018 Nov
TI  - Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 
      203 Patients from 12 Medical Centers in Israel.
PG  - 6423-6429
LID - 10.21873/anticanres.13003 [doi]
AB  - BACKGROUND/AIM: In this retrospective study, we summarized the national Israeli 
      experience with hairy cell leukemia (HCL) in a large cohort of patients with a 
      long follow-up. PATIENTS AND METHODS: Demographic data, and relevant laboratory 
      and clinical parameters were analyzed, emphasizing the outcome after first-line 
      treatment with cladribine. RESULTS: Data on 203 patients was collected from 12 
      medical centers during 1985-2015. Mean and median follow-up were 7.5 years and 
      5.18 years (interquartile range=0.1-40 years), and 5- and 10-year survival were 
      96% and 90.62%, respectively. The median age of diagnosis was 55.5 years for Jews 
      and 49 years for Arabs (p=0.021), and most patients were males (81.77%); 52.2% 
      were Ashkenazi Jews, 36.1% Sephardic Jews and 11.7% were Arab, Druze or other 
      ethnicity. Cladribine was given to 159 patients (80.7%%) and most (62%) received 
      intravenous (i.v.) and 38% received subcutaneous (s.c.) therapy. Overall survival 
      and time to next treatment were not significantly different between the two 
      schedules (i.v., s.c.). In univariate analysis of a variety of factors, only age 
      >65 years had a negative impact on outcome, with shorter overall survival. It is 
      of interest that Arab patients with HCL were diagnosed at an earlier age, but had 
      a similar clinical course and outcome to both Ashkenazi and Sephardic Jews.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Inbar, Michal
AU  - Inbar M
AD  - The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
FAU - Herishanu, Yair
AU  - Herishanu Y
AD  - Department of Hematology, Tel-Aviv Sourasky Medical Center and Sackler School of 
      Medicne, Tel-Aviv University, Tel Aviv, Israel.
FAU - Goldschmidt, Neta
AU  - Goldschmidt N
AD  - Department of Hematology, Hadassah University Hospital, Jerusalem, Israel.
FAU - Bairey, Osnat
AU  - Bairey O
AD  - Department of Hematology, Rabin Medical Center, Petah-Tikva, Israel.
FAU - Yuklea, Mona
AU  - Yuklea M
AD  - Department of Hematology, Meir Medical Center, Kfar-Saba, Israel.
FAU - Shvidel, Lev
AU  - Shvidel L
AD  - Hematology Unit, Kaplan Medical Center, Rehovot, Israel.
FAU - Fineman, Riva
AU  - Fineman R
AD  - Department of Hematology and Bone Marrow Transplantation, Rambam Health Care 
      Campus, Haifa, Israel.
FAU - Aviv, Ariel
AU  - Aviv A
AD  - Hematology Unit, Emek Medical Center, Afula, Israel.
FAU - Ruchlemer, Rosa
AU  - Ruchlemer R
AD  - Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
FAU - Braester, Andrei
AU  - Braester A
AD  - Hematology Unit, Galilee Medical Center, Naharia, Israel.
FAU - Najib, Dally
AU  - Najib D
AD  - Hematology Unit, Ziv Medical Center, Zefat, Israel.
FAU - Rouvio, Ory
AU  - Rouvio O
AD  - Department of Hematology, Soroka University Medical Center, Beer-Sheva, Israel.
FAU - Shaulov, Adir
AU  - Shaulov A
AD  - Department of Hematology, Hadassah University Hospital, Jerusalem, Israel.
FAU - Greenbaum, Uri
AU  - Greenbaum U
AD  - Department of Hematology, Soroka University Medical Center, Beer-Sheva, Israel.
FAU - Polliack, Aaron
AU  - Polliack A
AD  - Department of Hematology, Hadassah University Hospital, Jerusalem, Israel.
FAU - Tadmor, Tamar
AU  - Tadmor T
AD  - The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 
      tamar.tadmor@b-zion.org.il.
AD  - Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 47M74X9YT5 (Cladribine)
SB  - IM
MH  - Administration, Intravenous
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*administration & dosage/therapeutic use
MH  - Cladribine/*administration & dosage/therapeutic use
MH  - Early Detection of Cancer
MH  - Female
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Israel/ethnology
MH  - Leukemia, Hairy Cell/diagnosis/*drug therapy/*ethnology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Time-to-Treatment
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - HCL
OT  - Hairy cell leukemia
OT  - cladribine
OT  - ethnicity
OT  - intravenous
OT  - subcutaneous
EDAT- 2018/11/07 06:00
MHDA- 2018/11/14 06:00
CRDT- 2018/11/07 06:00
PHST- 2018/09/10 00:00 [received]
PHST- 2018/09/18 00:00 [revised]
PHST- 2018/10/08 00:00 [accepted]
PHST- 2018/11/07 06:00 [entrez]
PHST- 2018/11/07 06:00 [pubmed]
PHST- 2018/11/14 06:00 [medline]
AID - 38/11/6423 [pii]
AID - 10.21873/anticanres.13003 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Nov;38(11):6423-6429. doi: 10.21873/anticanres.13003.